首页> 美国卫生研究院文献>Biomedicines >Study of the Relationship between Sigma Receptor Expression Levels and Some Common Sigma Ligand Activity in Cancer Using Human Cancer Cell Lines of the NCI-60 Cell Line Panel
【2h】

Study of the Relationship between Sigma Receptor Expression Levels and Some Common Sigma Ligand Activity in Cancer Using Human Cancer Cell Lines of the NCI-60 Cell Line Panel

机译:利用NCI-60细胞系列癌细胞系癌细胞癌细胞系σ受体表达水平与癌症中常见Sigma配体活性的关系研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Sigma (σ) receptors have attracted great interest since they are implicated in various cellular functions and biological processes and diseases, including various types of cancer. The receptor family consists of two subtypes: sigma-1 (σ1) and sigma-2 (σ2). Both σ receptor subtypes have been proposed as therapeutic targets for various types of cancers, and many studies have provided evidence that their selective ligands (agonists and antagonists) exhibit antiproliferative and cytotoxic activity. Still, the precise mechanism of action of both σ receptors and their ligands remains unclear and needs to be elucidated. In this study, we aimed to simultaneously determine the expression levels of both σ receptor subtypes in several human cancer cell lines. Additionally, we investigated the in vitro antiproliferative activity of some widely used σ1 and σ2 ligands against those cell lines to study the relationship between σ receptor expression levels and σ ligand activity. Finally, we ran the NCI60 COMPARE algorithm to further elucidate the cytotoxic mechanism of action of the selected σ ligands studied herein.
机译:Sigma(σ)受体引起了极大的兴趣,因为它们涉及各种细胞功能和生物过程和疾病,包括各种类型的癌症。受体家族由两个亚型:Sigma-1(σ1)和Sigma-2(σ2)组成。已经提出了两种σ受体亚型作为各种类型癌症的治疗靶标,许多研究提供了证据表明其选择性配体(激动剂和拮抗剂)表现出抗增殖和细胞毒性活性。仍然,σ受体和它们配体的精确作用机制及其配体仍然不清楚,并且需要阐明。在该研究中,我们旨在同时确定几种人类癌细胞系中σ受体亚型的表达水平。另外,我们研究了一些广泛使用的σ1和σ2配体的体外抗增殖活性,针对那些细胞系来研究σ受体表达水平与σ配体活性之间的关系。最后,我们运行了NCI60比较算法,以进一步阐明本文所研究的所选σ配体的细胞毒性机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号